Kymera Therapeutics, Inc.
NASDAQ:KYMR · NASDAQ Global Market
+$1.50 today
Vol 1.17M · Avg 0.58M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:KYMR · Revenue to Net Income
Key Ratios
Analysis
$51.5M of revenue converted into -$315.1M of net income for the selected period. Gross margin is 91.2% and net margin is -1721.3%, showing how much revenue survives after costs and taxes. EPS is $-3.58, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39.2M -16.7% | $47.1M -40.1% | $78.6M +67.8% | $46.8M -35.7% | $72.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $39.2M -16.7% | $47.1M -40.1% | $78.6M +67.8% | $46.8M -35.7% | $72.8M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $316.6M +31.8% | $240.2M +27.1% | $189.1M +15.1% | $164.2M +19.9% | $137.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $68.2M +7.3% | $63.5M +15.4% | $55.0M +25.6% | $43.8M +20.6% | $36.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $388.6M +25.9% | $308.7M +26.5% | $244.1M +17.3% | $208.1M +20.0% | $173.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $8.3M +12.7% | $7.4M +106.8% | $3.6M +19.8% | $3.0M +24.2% | $2.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$303.1M -40.2% | -$216.2M -51.0% | -$143.2M +5.6% | -$151.7M -55.3% | -$97.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -773.1% -313.7pp | -459.4% -277.2pp | -182.2% +141.7pp | -323.9% -189.8pp | -134.1% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$349.4M -33.5% | -$261.6M -58.1% | -$165.5M -2.7% | -$161.3M -60.4% | -$100.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -891.3% -335.5pp | -555.8% -345.2pp | -210.6% +133.8pp | -344.4% -206.3pp | -138.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $38.0M +0.0% | $38.0M +102.7% | $18.8M +183.3% | $6.6M +1257.4% | $488.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $249.0K +0.0% | $249.0K +27.0% | $196.0K +11.4% | $176.0K +0.6% | $175.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $37.8M +0.0% | $37.8M +103.5% | $18.6M +188.0% | $6.4M +1960.1% | $313.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$311.6M -39.2% | -$223.9M -52.3% | -$147.0M +5.1% | -$154.8M -54.5% | -$100.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -795.0% -319.4pp | -475.6% -288.6pp | -187.0% +143.6pp | -330.6% -193.0pp | -137.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$311.4M -39.1% | -$223.9M -52.3% | -$147.0M +5.1% | -$154.8M -54.5% | -$100.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | -794.4% -318.8pp | -475.6% -288.6pp | -187.0% +143.6pp | -330.6% -193.0pp | -137.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$4 -23.8% | -$3 -18.3% | -$3 +12.2% | -$3 -37.3% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$4 -23.8% | -$3 -18.3% | -$3 +12.2% | -$3 -37.3% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $84.4M +12.5% | $75.0M +28.6% | $58.4M +8.2% | $53.9M +12.4% | $48.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $84.4M +12.5% | $75.0M +28.6% | $58.4M +8.2% | $53.9M +12.4% | $48.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Immunovant, Inc.
NASDAQ:IMVT
$7.26B
Arcellx, Inc.
ACLX
$6.73B
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$6.06B
Akero Therapeutics, Inc.
AKRO
$4.50B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.84B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.70B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.61B
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
$3.60B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Ascentage Pharma Group International
NASDAQ:AAPG
$403.46M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does KYMR generate?
Kymera Therapeutics, Inc. (KYMR) reported $39.20M of revenue in fiscal 2025.
Is KYMR profitable?
Kymera Therapeutics, Inc. (KYMR) reported -$311,400,000.00 of net income, with a net margin of -794.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.